Recently, many advances have been made in the field of oncological immunotherapy and the microbiota has proved to be fundamental in the response of patients to this new type of cancer approach.
In fact, studies have shown that the intestinal microbiome influences the response to immune-oncology drugs such as anti-PD1 / PDL1 in different types of cancer and the transplantation of faecal microbiota could lead to significant clinical benefits.
We interviewed Laurence Zitvogel, oncologist of the Institut Gustave Roussy in Paris and author of numerous publications in the most important scientific journals.
